Affimed N.V. (AFMD)
NASDAQ: AFMD · IEX Real-Time Price · USD
5.15
-0.29 (-5.33%)
At close: Jul 19, 2024, 4:00 PM
5.11
-0.04 (-0.78%)
Pre-market: Jul 22, 2024, 4:24 AM EDT
Affimed Revenue
Affimed had revenue of $4.26M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $168.48K. In the year 2023, Affimed had annual revenue of $9.19M.
Revenue (ttm)
$4.26M
Revenue Growth
-89.65%
P/S Ratio
18.41
Revenue / Employee
$56,064
Employees
76
Market Cap
78.42M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.19M | -34.80M | -79.10% |
Dec 31, 2022 | 43.99M | -1.88M | -4.09% |
Dec 31, 2021 | 45.87M | 11.29M | 32.63% |
Dec 31, 2020 | 34.59M | 10.55M | 43.90% |
Dec 31, 2019 | 24.03M | -3.25M | -11.90% |
Dec 31, 2018 | 27.28M | 24.87M | 1,031.03% |
Dec 31, 2017 | 2.41M | -4.23M | -63.70% |
Dec 31, 2016 | 6.64M | -1.57M | -19.10% |
Dec 31, 2015 | 8.21M | 4.12M | 100.71% |
Dec 31, 2014 | 4.09M | -2.90M | -41.50% |
Dec 31, 2013 | 7.00M | 5.45M | 352.11% |
Dec 31, 2012 | 1.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Protalix BioTherapeutics | 59.65M |
Alpha Teknova | 36.85M |
DBV Technologies | 14.94M |
Hyperfine | 11.69M |
Chimerix | 41.00K |
AFMD News
- 5 weeks ago - Affimed Reports First Quarter 2024 Financial Results & Business Update - GlobeNewsWire
- 6 weeks ago - Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024 - GlobeNewsWire
- 7 weeks ago - Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort - GlobeNewsWire
- 7 weeks ago - Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer - GlobeNewsWire
- 7 weeks ago - Affimed Announces Annual General Meeting of Shareholders - GlobeNewsWire
- 2 months ago - Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 - GlobeNewsWire
- 2 months ago - Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress - GlobeNewsWire
- 3 months ago - Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology - GlobeNewsWire